Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / LMDX - LumiraDx stock rises as COVID/influenza tests get CE mark in Europe

LMDX - LumiraDx stock rises as COVID/influenza tests get CE mark in Europe

LumiraDx Limited
London-based LumiraDx (NASDAQ:LMDX) said its Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete tests received CE marking in the EU. The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete test allows for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2, the company said in a June 8 press release. Meanwhile, the Dual-Target SARS-CoV-2 STAR Complete multiplex test simultaneously detects two gene markers to identify the presence of SARS-CoV-2, which will meet certain regulatory requirements in numerous regions that need two or more targets for a COVID-19 diagnostic, according to the company. LMDX +21.65% to $4.72 premarket June 8

For further details see:

LumiraDx stock rises as COVID/influenza tests get CE mark in Europe
Stock Information
Company Name: LumiraDx Limited
Stock Symbol: LMDX
Market: NASDAQ
Menu
LMDX LMDX Quote LMDX Short LMDX News LMDX Articles LMDX Message Board
Get LMDX Alerts

News, Short Squeeze, Breakout and More Instantly...